<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01203228</url>
  </required_header>
  <id_info>
    <org_study_id>2005-002011-24</org_study_id>
    <secondary_id>EBMT 42205525</secondary_id>
    <nct_id>NCT01203228</nct_id>
  </id_info>
  <brief_title>Dose-reduced Versus Standard Conditioning in MDS/sAML</brief_title>
  <acronym>RICMAC</acronym>
  <official_title>Dose-reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study (RICMAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Group for Blood and Marrow Transplantation</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Afssaps - French Health Products Safety Agency</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial dose reduced conditioning is compared to standard conditioning followed by
      allogeneic stem cell transplantation from related or unrelated donors in patients with MDS
      or secondary AML.

      Conditioning is the very high dose chemotherapy treatment that is given in the days before
      the stem cell transplant.

      The hypothesis is that a dose reduced conditioning will reduce the non-relapse mortality
      from 40% to 20% at one year after allogeneic stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>non-relapse mortality</measure>
    <time_frame>every 6 months for safety and in the final analysis at one year after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>organ related toxicity of conditioning</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +30  after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of aGVHD</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +100 after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of cGVHD</measure>
    <time_frame>every 6 months for safety and in the final analysis at one year after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>every 6 months for safety and in the final analysis at 2 years after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival</measure>
    <time_frame>every 6 months for safety and in the final analysis at 2 years after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>every 6 months for safety and in the final analysis at 2 years after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VOD</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +100 after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection incidence</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +100, 1 year and 2 years after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematopoeitic recovery</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +30 after allogeneic stem cell transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Myeloablative conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced Intensity Conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reduced Intensity Conditioning</intervention_name>
    <description>Busilvex®:
6.4 mg/kg IBW i. v. day -7:   0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6:   0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)
or (if i.v.-application is not available)
Busulfan:
8.0 mg/kg BW p. o.: day -7:   4.0 mg/kg BW day -6:   4.0 mg/kg BW
plus:
Fludarabine:
5 x 30 mg/m² BS i. v.: day -7:   30 mg/m² BS day -6:   30 mg/m² BS day -5:   30 mg/m² BS day -4:   30 mg/m² BS day -3:   30 mg/m² BS</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Myleran</other_name>
    <other_name>Sulphabutin</other_name>
    <other_name>Busulphan</other_name>
    <other_name>Leucosulfan</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Citosulfan</other_name>
    <other_name>Mielevcin</other_name>
    <other_name>Milecitan</other_name>
    <other_name>Fludara</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludura</other_name>
    <other_name>FAMP</other_name>
    <other_name>2-Fluoro-ara-AMP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Myeloablative conditioning</intervention_name>
    <description>Busilvex®:
12.8 mg/kg IBW i. v.; day -9:   0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8:   0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7:   0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6:   0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)
or (if i.v.-application is not available):
Busulfan:
16.0 mg/kg BW p. o.; day -9:   4.0 mg/kg BW day -8:   4.0 mg/kg BW day -7:   4.0 mg/kg BW day -6:   4.0 mg/kg BW
plus:
Cyclophosphamide:
120 mg/kg BW i. v.; day -4:   60 mg/kg BW day -3:   60 mg/kg BW</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Myleran</other_name>
    <other_name>Sulphabutin</other_name>
    <other_name>Busulphan</other_name>
    <other_name>Leucosulfan</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Citosulfan</other_name>
    <other_name>Mielevcin</other_name>
    <other_name>Milecitan</other_name>
    <other_name>cyclophosphamide</other_name>
    <other_name>Procytox</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Claphene</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disease: Cytologically proven primary or therapy-related myelodysplastic syndrome
             (MDS), either as

               -  refractory anaemia (RA) according FAB or RA with or without dysplasia according
                  WHO,

               -  refractory anaemia with ringsideroblasts (RARS) according FAB or RARS with or
                  without dysplasia according WHO,

               -  refractory anaemia with excess of blasts (RAEB) according FAB or RAEB I or RAEB
                  II according WHO,

               -  refractory anaemia with excess of blast in transformation (RAEB T) according
                  FAB,

               -  CMML (dysplastic type) according WHO,

          -  or secondary acute myeloid leukaemia (sAML).

          -  Blast count &lt; 20 percent in bone marrow with or without chemotherapy at time of
             transplantation.

          -  Patient eligible for standard and dose-reduced conditioning as per local guideline.

          -  Patient age 18 - 60 years if donor is a HLA-matched unrelated donor (HLA-A, HLA-B,
             HLA-DRB1 and HLA-DQB1) (one mismatch allowed):

          -  Patient age 18 - 65 years if donor is a HLA-matched related donor ((HLA-A, HLA-B,
             HLA-DRB1 and HLA-DQB1) (one anti¬gen-mismatch allowed):

          -  No major organ dysfunction.

          -  Written informed consent of the patient.

        Exclusion Criteria:

          -  Blasts &gt; 20 % in bone marrow at time of transplantation

          -  No written informed consent.

          -  Central nervous involvement.

          -  Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as

          -  Total bilirubin, SGPT or SGOT &gt; 2 times upper the normal level.

          -  Left ventricular ejection fraction &lt; 30 %.

          -  Creatinine clearance &lt; 30 ml/min.

          -  DLCO &lt; 35 % and/or receiving supplementary continuous oxygen.

          -  Positive serology for HIV.

          -  Pregnant or lactating women.

          -  Patients with a life-expectancy of less than six months because of another
             debilitating disease.

          -  Serious psychiatric or psychological disorders.

          -  Invasive fungal infection at time of registration.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kröger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theo de Witte, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Nijmegen. The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Axel R Zander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Hamburg-Eppendorf, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ghulam J Mufti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Robin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Saint-Louis Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hartmut Biersack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Schmid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Augsburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathrin Haifa Al-Ali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dietger Niederwieser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Onida, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Ospedale Maggiore of Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alois Gratwohl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tapani Ruutu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giorgio Lambertenghi Deliliers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Ospedal Maggiore di Milano, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Augustin Ferrant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St. Luc Bruxelles, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolaus Kröger, MD</last_name>
    <phone>+49-40-42803-4850</phone>
    <email>nkroeger@uke.uni-hamburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruzena Uddin</last_name>
    <phone>0044 207 1888598</phone>
    <email>ruzena.uddin@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kobbe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kobbe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weber, MD</last_name>
    </contact>
    <investigator>
      <last_name>Weber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Kröger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolaus Kröger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dengler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dengler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKSH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fastenrath, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fastenrath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hübel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hübel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Al Ali, MD</last_name>
    </contact>
    <investigator>
      <last_name>Al Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Munster</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthias Stelljes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethge, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bethge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santi Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernardino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernardino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guidi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Onida, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lamberthengi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Onida, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University MC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theo de Witte, MD</last_name>
    </contact>
    <investigator>
      <last_name>Theo de Witte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPb State I. Pavlov Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Afanassiev, MD</last_name>
    </contact>
    <investigator>
      <last_name>Boris Afanassiev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 4, 2011</lastchanged_date>
  <firstreceived_date>September 15, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Ruzena Uddin</name_title>
    <organization>EBMT (European Group for Blood and Marrow Transplantation)</organization>
  </responsible_party>
  <keyword>Reduced Intensity conditioning</keyword>
  <keyword>Myeloablative conditionig</keyword>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>MUD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine monophosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
</clinical_study>
